Disease Areas:
COPD, CoughDevice Types:
VitaloJAKThis Phase IIa randomized, double-blind, crossover study evaluated the efficacy, pharmacokinetics, and safety of navafenterol, as compared with placebo or umeclidinium/vilanterolan, in 73 patients with moderate-to-severe COPD. The study assessed reduction in cough as an exploratory endpoint, which was objectively measured using the Vitalograph VitaloJAK cough monitor.